TCG Advisory Services LLC Has $1.23 Million Holdings in Pfizer Inc. (NYSE:PFE)

TCG Advisory Services LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 157.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,710 shares of the biopharmaceutical company’s stock after acquiring an additional 26,145 shares during the quarter. TCG Advisory Services LLC’s holdings in Pfizer were worth $1,230,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley boosted its stake in shares of Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after buying an additional 348,628 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Pfizer by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after acquiring an additional 5,185,453 shares in the last quarter. Invesco Ltd. increased its stake in shares of Pfizer by 30.9% in the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after acquiring an additional 5,678,004 shares during the last quarter. Finally, California Public Employees Retirement System raised its holdings in shares of Pfizer by 0.6% during the third quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock worth $609,692,000 after acquiring an additional 101,256 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock traded up $0.11 during trading on Friday, reaching $27.81. 60,568,852 shares of the stock were exchanged, compared to its average volume of 41,900,304. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $157.48 billion, a P/E ratio of -463.42, a price-to-earnings-growth ratio of 1.18 and a beta of 0.63. The stock has a 50 day simple moving average of $26.88 and a 200-day simple moving average of $28.21.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.23 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.36 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio is -2,799.53%.

Analyst Ratings Changes

A number of research firms have recently weighed in on PFE. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.